EASL 2020
The Digital ILC 2020
August 27—29, 2020
To help you get as much value from Digital ILC as possible, we have identified 15-20 presentations and posters we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.
Thursday Aug 27, 2020
Our Surfers Discussed The Following Papers and Sessions on Day 1
Roger Green — AS101 Convolutional neural networks of H&E stained biopsy images accurately quantify histologic features of non-alcoholic steatohepatitis
Donna Cryer — AS098 Machine learning outperforms existing non-invasive tests as a screening tool for liver fibrosis in the general population.
Peter Traber, MD — Session Optimal endpoints in NAFLD clinical Trials: Histology or non-invasive biomarkers and imaging?
Louise Campbell MSc AP — Session Patients for nonalcoholic fatty liver disease referred from primary care have a significant serum fibrosis marker and liver stiffness measurement discordance.
and
AS160: Multidisciplinary team approach to nonalcoholic fatty liver disease improves cardiovascular risk factors
Dr. Stephen Harrison — AS100 Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with non-alcoholic fatty liver disease
Naim Alkhouri, M.D. — AS157 Liver Disease Progression and Clinical Outcomes, and a registry called the, “Hepatic Outcomes and Survival Fatty Liver Registry,” or the “HOTSURFR Study.”
Surfing The NASH Tsunami Podcast Day 1
Friday Aug 28, 2020
Our Surfers Will Discuss The Following Papers and Sessions on Day 2
Louise Campbell MSc AP — AS064: Incorporating assessment of liver fibrosis into routine diabetic review in primary care or pilot.
Dr. Stephen Harrison — Abstract Session: Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo controlled Phase 2 clinical trial
Donna Cryer — AS017: A polygenic risk score for progressive nonalcoholic fatty liver disease risk stratification
Roger Green — AS15: Therapeutic effect of a novel long-acting GLP-1, GIP, glucagon triple agonist in animal models of NASH and fibrosis
Peter Traber, MD — Abstract Session: Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: A phase 2 randomized controlled trial (FASCINATE-1)
Vlad Ratziu, MD, PhDM — AS078 EDP-305
A non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a ARGON-1 study
Saturday, Aug 29, 2020
Our Surfers Discussed The Following Papers and Sessions on Day 3
Donna Cryer — AS018: Carbohydrate restriction reverses NAFLD by altering hepatic mitochondrial fluxes in humans.
Louise Campbell MSc AP — SAT249: The variscreen algorithm using successively platelets, liver stiffness, and INR improves and secures the screening of esophageal varies needing treatment.
Peter Traber, MD — LB004: Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
Dr. Stephen Harrison — LB001: Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis
Roger Green — Covid and the Liver: Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis
Surfing The NASH Tsunami Podcast Day 3
Available In Your Favorite Podcast App:
